Can chatbots help with genetic testing for cancer risk?

AI SummaryThe demand for cancer genetic testing is increasing, but there is a shortage of genetic counselors to assist patients. Researchers suggest that chatbots could potentially help with this issue by guiding patients through the genetic testing process. This innovation could make genetic testing more accessible and efficient for individuals seeking information about their cancer… Continue reading Can chatbots help with genetic testing for cancer risk?

EMA Refuses Marketing Authorization for Alzheimer’s Drug

AI SummaryThis article discusses how the EU has refused to grant marketing authorization for Leqembi, a drug for Alzheimer’s, due to concerns about its risk of serious adverse events outweighing its ability to delay cognitive decline.Leqembi’s EU-wide marketing authorization was refused because the drug’s effect on delaying cognitive decline does not counterbalance the risk for… Continue reading EMA Refuses Marketing Authorization for Alzheimer’s Drug

Study across multiple brain regions discerns Alzheimer’s vulnerability and resilience factors

AI SummaryThis study published in Nature by MIT researchers focused on discerning Alzheimer’s vulnerability and resilience factors in the brain by analyzing gene expression across multiple brain regions. The research identified vulnerable neurons associated with cognitive decline due to Alzheimer’s pathology, notably those producing the Reelin protein. Additionally, the study highlighted astrocytes expressing genes linked… Continue reading Study across multiple brain regions discerns Alzheimer’s vulnerability and resilience factors

Real‐world genetic testing outcomes of pan‐cancer testing for mismatch repair deficiency

AI SummaryThis study explored the outcomes of pan-cancer testing for mismatch repair deficiency, specifically focusing on the identification of Lynch syndrome. Results showed that MMR testing identified LS cases at a rate similar to universal CRC and EC screening programs, with LS being most commonly found in patients with brain and small intestinal cancers. The… Continue reading Real‐world genetic testing outcomes of pan‐cancer testing for mismatch repair deficiency

Real‐world genetic testing outcomes of pan‐cancer testing for mismatch repair deficiency

AI SummaryThis study examines real-world genetic testing outcomes of pan-cancer testing for mismatch repair deficiency, focusing on the identification of Lynch syndrome (LS) cases. MMR immunohistochemistry testing was found to be beneficial for all tumor types, not just for screening for LS. The study found that pan-cancer MMR testing can identify LS cases at a… Continue reading Real‐world genetic testing outcomes of pan‐cancer testing for mismatch repair deficiency

Population-based germline breast cancer gene association studies and meta-analysis to inform wider mainstream testing.

AI SummaryThis article discusses population-based germline breast cancer gene association studies and meta-analysis as a means to provide information for wider mainstream testing. It mentions the increasing trend of genetic testing being offered to a broader population of breast cancer patients and highlights the variation in genes included in these tests. This research aims to… Continue reading Population-based germline breast cancer gene association studies and meta-analysis to inform wider mainstream testing.